Form 4: Tempest Therapeutics Director Ronit Simantov Acquires Stock Options

Director Ronit Simantov acquired stock options for 16,000 shares of Tempest Therapeutics common stock on June 13, 2024.

Summary

• Ronit Simantov, a director of Tempest Therapeutics, Inc., acquired stock options on June 13, 2024.
• The options grant the right to buy 16,000 shares of Tempest Therapeutics common stock at an exercise price of $3.03 per share.
• The options vest fully on the earlier of June 13, 2025, or the date of the Issuer's 2025 annual stockholder meeting, contingent upon continuous service.
• Following the transaction, Simantov directly owns options for 16,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could signal confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continuous service, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to track the buying and selling activity of individuals with privileged information about the company.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's success.

Key Dates